Results 151 to 160 of about 2,105 (188)
A phase II trial of marimastat in advanced pancreatic cancer [PDF]
British Journal of Cancer, 2001 Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy. Inhibition of matrix metalloproteinase activity involved in tumour invasion and metastases is a novel biological approach for cancer treatment. This multicentre phase II clinical trial assessed marimastat, an oral matrix metalloproteinase inhibitor, in patients with ...
J P Neoptolemos
exaly +6 more sources
The interaction of metal ions and Marimastat with matrix metalloproteinase 9
Journal of Inorganic Biochemistry, 2003 The effect of a range of metal ions on the ability of Marimastat to inhibit matrix metalloproteinase 9 (MMP-9) was examined in a fluorescence based proteolytic assay. Whilst none of the metals examined significantly affected the inhibitory ability of Marimastat, several metal ions did have a significant effect on MMP-9 activity itself.
Trevor Hambley, T W Hambley
exaly +7 more sources
European Journal of Cancer, 1999 The aim of this study was to evaluate the safety and tolerability of 4 weeks administration of marimastat, and to seek evidence of biological activity as observed by changes in the endoscopic appearance of the gastric tumours. 35 patients with advanced, inoperable gastric or gastro-oesophageal tumours were recruited.
R J C Steele, P D Brown
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Marimastat: the clinical development of a matrix metalloproteinase inhibitor
Expert Opinion on Investigational Drugs, 2000Marimastat (BB-2516) is the first orally bioavailable matrix metalloproteinase inhibitor to have entered clinical trials in the field of oncology. It has excellent bioavailability and has completed Phase I, II and some Phase III trials. In Phase I studies, which recruited patients with various malignancies, the main toxicity observed was mild to severe
Anne Thomas +2 more
exaly +4 more sources
Marimastat (BB2516): Current status of development
Cancer Chemotherapy and Pharmacology, 1999Marimastat (BB-2516) is the first matrix metalloproteinase inhibitor to have entered clinical trials in the field of oncology. It has excellent bioavailability and has completed phase I and II trials. Phase I studies involved healthy volunteers who received short courses of marimastat; these were well tolerated.
W P Steward, William P Steward
exaly +4 more sources
Marimastat alleviates oxidative stress induced cellular senescence by activating autophagy
Biochemical and Biophysical Research Communications, 2022Marimastat is one of the potent inhibitors of MMP (MMPIs) with few side effects. The impact of marimastat on cellular senescence remains unexplored. Our study evaluated the marimastate effect on oxidative stress-induced cell senescence using NIH3T3 cells.
Jing, Xia +6 more
exaly +3 more sources
Bioorganic and Medicinal Chemistry, 2012 Lenger J, Kaschani F, Lenz T, et al. Labeling and enrichment of Arabidopsis thaliana matrix metalloproteases using an active-site directed, marimastat-based photoreactive probe. Bioorganic & Medical Chemistry.
Norbert Sewald, Renier van der Hoorn
exaly +2 more sources
Toxicology and Applied Pharmacology, 2005
This pilot study was designed to assess whether a synthetic matrix metalloproteinase (MMP) inhibitor has anti-inflammatory properties in mild asthma. Tumor necrosis factor alpha (TNFalpha) has been shown to be an important cytokine in the pathogenesis of allergic airway inflammatory responses, and its release can be inhibited by MMP inhibitors.
Paul Thomas
exaly +3 more sources
This pilot study was designed to assess whether a synthetic matrix metalloproteinase (MMP) inhibitor has anti-inflammatory properties in mild asthma. Tumor necrosis factor alpha (TNFalpha) has been shown to be an important cytokine in the pathogenesis of allergic airway inflammatory responses, and its release can be inhibited by MMP inhibitors.
Paul Thomas
exaly +3 more sources
Five-component synthesis of marimastat analogues
Tetrahedron Letters, 1998Abstract The synthesis of analogues of the matrix metalloproteinase (MMP) inhibitor marimastat has been achieved in one-pot by a two step procedure involving an Ugi four-component reaction followed by hydroxylaminolysis of an acetonide.
Sanjay Patel +4 more
openaire +1 more source
Marimastat in Patients With Advanced Pancreatic Cancer
American Journal of Clinical Oncology, 1999Patients with solid tumors, including carcinoma of the pancreas, express high levels of matrix metalloproteinases (MMP), and these enzymes are believed to be important for the growth, spread, and dissemination of most solid malignant tumors. Marimastat is the first orally available MMP inhibitor (MMPI) to be tested in humans and has been shown to ...
A, Rosemurgy +5 more
openaire +2 more sources